Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Conditions: Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Questionnaire Administration; Drug: Tamoxifen Citrate
Sponsors: National Cancer Institute (NCI)
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments